This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Menu
Follow UroToday
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Rana R. McKay, MD
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mCRPC Treatment
Charles Ryan, MD
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Neal Shore, MD, FACS
A Patient Journey
Alicia Morgans, MD, MPH
Charles J. Ryan, MD
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Transformative Evidence
mCRPC
CARD Trial
PROfound Study
mHSPC
ENZAMET Trial
nmCRPC
PROSPER Trial
Advanced Prostate Cancer
HERO Trial
Bladder Cancer
Bladder Cancer Detection
Videos
Conference Coverage and Experts Group
Interviews with Experts at Conferences
ASCO GU 2021 Bladder and Kidney Cancer
ASCO GU 2021 Prostate Cancer
ASCO 2019
ASCO 2020
ASCO GU 2020
ESMO 2020
Exclusive Collaborations
APCCC 2019
LUGPA Annual Meeting 2019
PCF 2019
SNMMI Curriculum
UroToday Exclusives
Provocative Questions in Prostate Cancer
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer
Book Club
Clinical Trials in Progress
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer
COVID-19 and Genitourinary Cancers Videos
Journal Club
Large Urology Group Practice Association (LUGPA)
Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Videos
Urologic Oncology
Prostate Cancer
Advances in Nuclear Medicine, PET, and Theranostics
Advanced Prostate Cancer
Cardiovascular Disease in Men with Prostate Cancer
CRPC with Bone Metastases
The Expert Voice
Imaging: Prostate Cancer
Localized Prostate Cancer
mCRPC
mHSPC
Molecular Diagnostics
Navigating Cancer
nmCRPC
The Patient Voice
Precision Medicine in Prostate Cancer
Prostate Cancer
Right Group
Bladder Cancer
Bladder Cancer
Bladder Cancer Expert Debates
Advanced Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Kidney Cancer
Advanced Kidney Cancer
Renal Cancer
Upper Tract Urothelial Tumors
Upper Tract Urothelial Carcinoma
Pelvic Health & Reconstruction
Bladder Health
Indwelling Catheters
Intermittent Catheters
Nocturia & Lower Urinary Tract Conditions
Endourology
Endourology Today
Endourology
Testicular Cancer
Testicular Cancer
Journals
Everyday Urology - Oncology Insights
From the Editor
Current Issue
Previous Issues
Prostate Cancer and Prostatic Diseases
From the Editor
Current Article
Previous Articles
Clinical Trials
Clinical Trials
Search Clinical Trials
From the Editor
Current Letter
Previous Letters
Conference Coverage
Advanced Prostate Cancer Consensus Conference (APCCC)
2019 APCCC Meeting
American Society of Clinical Oncology (ASCO)
2021 ASCO GU Symposium
2020 Virtual Education Program
2020 Annual Meeting
2020 ASCO GU Symposium
American Urological Association (AUA)
2021 Southeastern Section
2020 Annual Meeting
ANZUP Mini Annual Scientific Meeting (ASM)
2020 Virtual Annual Meeting
Bladder Cancer Advocacy Network (BCAN)
2020 Think Tank Virtual Program
EAU Section of Oncological Urology
ESOU 2021
EMUC
2020 Annual Meeting
European Association of Urology (EAU)
2020 Annual Congress
European Society for Medical Oncology (ESMO)
2020 Virtual Congress
Global Society of Rare GU Tumors
2020 Meeting
International Bladder Cancer Network (IBCN)
2020 Annual Virtual Meeting
NMIBC - Drug Development 2021
2021 Annual Meeting
Prostate Cancer Academy
2020 Annual Meeting
Société Internationale d'Urologie (SIU)
2020 Annual Congress
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
2021 Congress
2020 Congress
Society of Urologic Oncology (SUO)
2020 Annual Meeting
2020 SUO - AUA Summer Webcast
Targeted Alpha Therapy (TAT)
2019 Symposium
International Kidney Cancer Symposium (IKCS)
2021 European International Kidney Cancer Symposium (EIKCS)
Articles
Urologic Oncology
Adrenal Diseases
Bladder Cancer
CRPC w/ Bone Metastases
Penile Cancer
Prostate Cancer
Renal Cancer
Upper Tract Tumors
Investigative Urology
Testicular Cancer
Men's Health
Androgen Deficiency
BPH
Erectile Dysfunction
Male Infertility
Peyronie’s Disease
Prostatitis
Vasectomy
Pelvic Health & Reconstruction
Fecal Incontinence
Fistula
GU Trauma & Reconstruction
Indwelling Catheters
Infections
Intermittent Catheters
Interstitial Cystitis
Neurogenic Bladder
Nocturia
Overactive Bladder
Pelvic Prolapse
Post-prostatectomy Incontinence
Stress Incontinence
Underactive Bladder
Urethral Strictures
Urinary Incontinence
Urinary Retention
Urinary Tract Infection – CAUTIs
Urologic Catheters
Endourology & Urolithiasis
Minimally Invasive Procedures
Stone Disease
Pediatric Urology
Pediatric Urology
COVID-19 and Genitourinary Cancers
COVID-19 and Genitourinary Cancers
Calendar
UroToday Home
Transformative Evidence
ENZAMET Trial: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
COVID-19 and Genitourinary Cancers Videos
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin
Details
Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin
Details
Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (ENZAMET) - Tanya Dorff
Details
Tanya Dorff and Alicia Morgans discuss the ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer) trial design and key take-home messages based upon the ASCO 2019 plenary presentation by Christopher Sweeney. The investigators hypothesized that adding enzalutamide to first-line therapy would delay the emergence of castration resistance and thereby improve o...
Impact of Academic Collaborations in mHSPC Trial: ENZAMET - Chris Sweeney
Details
Chris Sweeney and Alicia Morgans discuss how the academic collaboration for ENZAMET (Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer) became a reality and initiated in November 2014. The ENZAMET study was led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. ENZAMET (ANZUP 1304) is a global collaborative investigator...
ENZAMET Trial - Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer - Christopher Sweeney
Details
Chris Sweeney and Alicia Morgans discuss the interim analysis of the international academic investigator-sponsored, randomized phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer who received the nonsteroidal antiandrogen agent enzalutamide along with standard-of-care treatment were alive after 3 years, compared with 72% of men who received other nonster...
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Details
Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers three main topics including systemic therapies, treatment of the primary, and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy, and ultimately cure, especially...
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans
Details
Alicia Morgans discusses the role of integrating patients in treatment decisions by incorporating quality of life, in particular when there are multiple treatments available with similar efficacy. Dr. Morgans emphasizes how patients should be included in the conversations and the decisions on treatment selection and considerations on efficacy, safety, and potential toxicities. She reiterates that...
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free